Champions Oncology (CSBR) vs Spero Therapeutics (SPRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Champions Oncology (CSBR) has outperformed Spero Therapeutics (SPRO) over the past year, losing 23.0% versus a loss of 49.2%. Over five years, CSBR leads with a -50.6% price change compared with -93.3% for SPRO. Spero Therapeutics is the larger company by market cap ($69.9 million vs $67.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSBR | SPRO |
|---|---|---|
| Share price | $4.84 | $1.20 |
| Market cap | $67.37M | $69.88M |
| 1-day change | -2.81% | +5.26% |
| YTD return | -27.93% | -48.50% |
| 1-year return | -23.03% | -49.15% |
| 5-year return | -50.60% | -93.30% |
| P/E ratio (TTM) | — | 8.57 |
| Forward P/E | 48.40 | — |
| EPS (TTM) | $-0.07 | $0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.31 | $3.08 |
| 52-week low | $4.59 | $1.08 |
| Distance from 52-week high | -41.76% | -61.04% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +316.67% |
| Average volume | 11.47K | 1.21M |
| Shares outstanding | 13.92M | 58.23M |
| Employees | 214 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSBR has outperformed SPRO by 26.1 percentage points over the past year.
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 214 employees
About Spero Therapeutics
SPRO stock →Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
CSBR vs SPRO FAQ
Which is bigger, Champions Oncology or Spero Therapeutics?
Spero Therapeutics (SPRO) is larger, with a market capitalization of $69.88M compared with $67.37M for Champions Oncology (CSBR).
Which stock has performed better over the past year, CSBR or SPRO?
CSBR returned -23.03% over the past 12 months, compared with -49.15% for SPRO (price return, excluding dividends). Past performance does not predict future results.
Are Champions Oncology and Spero Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Champions Oncology and Biotechnology: Pharmaceutical Preparations for Spero Therapeutics.